Literature DB >> 8675648

A unique genetic and biochemical presentation of fish-eye disease.

J A Kuivenhoven1, E J van Voorst tot Voorst, H Wiebusch, S M Marcovina, H Funke, G Assmann, P H Pritchard, J J Kastelein.   

Abstract

This paper describes a novel genetic defect which causes fish-eye disease in four homozygous probands and its biochemical presentation in 34 heterozygous siblings. The male index patient presented with premature coronary artery disease, corneal opacification, HDL deficiency, and a near total loss of plasma lecithin:cholesterol acyltransferase (LCAT) activity. Sequencing of the LCAT gene revealed homozygosity for a novel missense mutation resulting in an Asp131 - Asn (N131D) substitution. Heterozygotes showed a highly significant reduction of HDL-cholesterol and apolipoprotein A-I levels as compared with controls which was associated with a specific decrease of LpA-I:A-II particles. Functional assessment of this mutation revealed loss of specific activity of recombinant LCAT(N131D) against proteoliposomes. Unlike other mutations causing fish-eye disease, recombinant LCAT(N131D) also showed a 75% reduction in specific activity against LDL. These unique biochemical characteristics reveal the heterogeneity of phenotypic expression of LCAT gene defects within a range specified by complete loss of LCAT activity and the specific loss of activity against HDL. The impact of this mutation on HDL levels and HDL subclass distribution may be related to the premature coronary artery disease observed in the male probands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675648      PMCID: PMC185988          DOI: 10.1172/JCI118348

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

2.  Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol.

Authors:  G R Warnick; T Nguyen; A A Albers
Journal:  Clin Chem       Date:  1985-02       Impact factor: 8.327

3.  Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates.

Authors:  H J Parra; H Mezdour; N Ghalim; J M Bard; J C Fruchart
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Apolipoprotein A-I containing lipoproteins in coronary artery disease.

Authors:  P Puchois; A Kandoussi; P Fievet; J L Fourrier; M Bertrand; E Koren; J C Fruchart
Journal:  Atherosclerosis       Date:  1987-11       Impact factor: 5.162

6.  Evidence for deficiency of high density lipoprotein lecithin: cholesterol acyltransferase activity (alpha-LCAT) in fish eye disease.

Authors:  L A Carlson; L Holmquist
Journal:  Acta Med Scand       Date:  1985

7.  Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease.

Authors:  M Dobiasova; J Stribrna; D L Sparks; P H Pritchard; J J Frohlich
Journal:  Arterioscler Thromb       Date:  1991 Jan-Feb

8.  Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.

Authors:  M Burstein; H R Scholnick; R Morfin
Journal:  J Lipid Res       Date:  1970-11       Impact factor: 5.922

9.  Cloning and expression of human lecithin-cholesterol acyltransferase cDNA.

Authors:  J McLean; C Fielding; D Drayna; H Dieplinger; B Baer; W Kohr; W Henzel; R Lawn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene.

Authors:  R D Palmiter; R R Behringer; C J Quaife; F Maxwell; I H Maxwell; R L Brinster
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

View more
  10 in total

1.  A first British case of fish-eye disease presenting at age 75 years: a double heterozygote for defined and new mutations affecting LCAT structure and expression.

Authors:  A F Winder; J S Owen; P H Pritchard; D Lloyd-Jones; D T Vallance; P White; R Wray
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

2.  A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I.

Authors:  Kelly A Manthei; Joomi Ahn; Alisa Glukhova; Wenmin Yuan; Christopher Larkin; Taylor D Manett; Louise Chang; James A Shayman; Milton J Axley; Anna Schwendeman; John J G Tesmer
Journal:  J Biol Chem       Date:  2017-10-13       Impact factor: 5.157

3.  An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).

Authors:  J A Kuivenhoven; H Weibusch; P H Pritchard; H Funke; R Benne; G Assmann; J J Kastelein
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

4.  Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis.

Authors:  Eric J Brandt; Shane M Regnier; Edward Ky Leung; Sharon H Chou; Beverly W Baron; Helen S Te; Michael H Davidson; Robert M Sargis
Journal:  Clin Lipidol       Date:  2015-08-01

Review 5.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

Review 6.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

7.  Interaction of lecithin:cholesterol acyltransferase with lipid surfaces and apolipoprotein A-I-derived peptides.

Authors:  Marco G Casteleijn; Petteri Parkkila; Tapani Viitala; Artturi Koivuniemi
Journal:  J Lipid Res       Date:  2018-02-08       Impact factor: 5.922

8.  Positive allosteric modulators of lecithin: Cholesterol acyltransferase adjust the orientation of the membrane-binding domain and alter its spatial free energy profile.

Authors:  Akseli Niemelä; Artturi Koivuniemi
Journal:  PLoS Comput Biol       Date:  2021-03-15       Impact factor: 4.475

Review 9.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

10.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.